AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura

RecruitingPhase 2Ages 18 Years - 80 YearsAllCentre Hospitalier Universitaire de Nice
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Recent data suggest involvement of Acid-Sensing Ion Channel channels in the pathophysiology of migraine making these channels a therapeutic target of migraine disease. The implication of Acid-Sensing Ion Channels is discussed through Acid-Sensing Ion Channel-1 which is the most expressed Acid-Sensing Ion Channel channel subtype in the central nervous system. In a mouse model, cortical spreading depression is inhibited by different Acid-Sensing Ion Channel blockers including amiloride which is a non-selective blocker of the Acid-Sensing Ion Channel-1 channel. From a translational perspective, an efficacy of amiloride on a series of migraine patients suffering from severe aura in open conditions. The APAM study is a proof-of-concept study that aims to evaluate the effect of amiloride in the prophylaxis of migraine with aura. This is a randomized crossover study versus placebo conducted in

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of migraine with aura code * At least 1 aura with aura per month in the 3 months prior to inclusion * No prophylactic antimigraine treatment for at least 1 month prior to inclusion * For women of childbearing age, use of a reliable contraceptive method at least 3 months before and 1 month after the study * Signature of written informed consent * Patient affiliated with Social Security Exclusion Criteria: * Existence of contraindication to taking amiloride: * Known hypersensitivity to the molecule * Hyperkalemia (potassium level (\> 5.5 mmol / l)) * Use of another hyperkalemic diuretic or potassium salts * Renal insufficiency (clearance \<60 ml / min) * Severe hepatocellular insufficiency * In combination with lithium, converting enzyme inhibitors, angiotensin II inhibitors (except if there is hypokalemia), ciclosporin, tacrolimus, non-antiarrhythmic drugs giving torsades de pointes * Cardiovascular and renal history, for subjects over 75 years old * Patient, who from an investigator's point of view would not be compliant to the procedure of the study * Pregnant or lactating patient * Patient under trusteeship, under guardianship, protected by law
๐Ÿ’Š

What it tests

  • Amiloride
  • Placebos
๐Ÿ“

Where

5 sites
Hรดpital Pierre Wertheimer
Bron, France
CHU Gabriel Montpied
Clermont-Ferrand, France
AP-HM
Marly, France
CHU de Montpellier
Montpellier, France
CHU de NICE
Nice, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy